At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 12, 2026 at 16:01 ET
BlossomHill Therapeutics reported Q3 2026 net loss of $24.0M ($1.29 per share), wider than the $16.0M loss in Q3 2025, driven by increased R&D spending on lead programs. The company highlighted FDA alignment on a Phase 2 dose for BH-30643 and plans for a pivotal trial, with $224.9M cash expected to fund operations into Q2 2028. Consensus estimates were not available for EPS or revenue, so no surprise or rating is assigned.
- Net loss of $24.0M ($1.29 per share) for Q3 2026 vs $16.0M ($6.54 per share) in Q3 2025
- Cash and cash equivalents of $224.9M as of September 30, 2026
- FDA alignment on 50 mg BID as recommended Phase 2 dose for BH-30643
- SOLARA-2 pivotal Phase 2 trial for BH-30643 in C797S-positive NSCLC expected to dose first patient in Q1 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access